Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection

Digestive Diseases and Sciences

Volumn 56, Issue 1, 2011, Pages 208-212

  Senturk, Hakan ^a   Baysal, Birol ^a   Tahan, Veysel ^b   Zerdali, Hasan ^a   Ozaras, Resat ^a   Tabak, Fehmi ^a   Mert, Ali ^a   Canbakan, Billur ^a   Tabak, Omur ^c   Ozbay, Gulsen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Istanbul Education and Training Hospital ^*  (Turkey)

Author keywords

Chronic hepatitis B; Genotype; HBeAg; Interferon; Sustained response; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79151475101     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1255-9     Document Type: Article

References (20)

1. M van Zonneveld P Honkoop BE Hansen HGM Niesters SD Murad RA de Man, et al. 2004 Long-term follow-up of alfa-interferon treatment of patients with chronic hepatitis B Hepatology 39 804 810 10.1002/hep.20128 14999700
2. C Niederau T Heintges S Lange G Goldmann CM Niederau L Mohr D Häussinger 1996 Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1422 1427 1:STN:280:DyaK283hvVyhtw%3D%3D 10.1056/NEJM199605303342202 8618580
3. G Fattovich G Giustina G Realdi R Corrocher SW Schalm 1997 Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 26 1338 1342 1:CAS:528:DyaK2sXntl2jtLg%3D 10.1002/hep.510260536 9362381
4. EH Buster HJ Flink Y Cakaloglu K Simon J Trojan F Tabak TM So SV Feinman T Mach US Akarca M Schutten W Tielemans AJ van Vuuren BE Hansen HL Janssen 2008 Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b Gastroenterology 135 459 467 1:CAS:528:DC%2BD1cXhtVCqsL%2FK 10.1053/j.gastro.2008.05.031 18585385
5. DTY Lau J Everhart DE Kleiner Y Park J Vergalla P Schmid, et al. 1997 Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1660 1667 1:CAS:528:DyaK2sXnt1yhtr4%3D 10.1053/gast.1997.v113.pm9352870 9352870
6. EH Buster BE Hansen M Buti J Delwaide C Niederau PP Michielsen R Flisiak PE Zondervan SW Schalm HL Janssen HBV 99-01 Study Group 2007 Peginterferon alfa-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis Hepatology 46 388 394 1:CAS:528:DC%2BD2sXhtVSmu7nJ 10.1002/hep.21723 17604363
7. M Sunbul H Leblebicioglu 2005 Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey World J Gastroenterol 11 1976 1980 1:CAS:528:DC%2BD2MXktFyru7c%3D 15800989
8. RG Knodell KG Ishak WC Black TS Chen R Craig N Kaplowitz TW Kiernan J Wollman 1981 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 431 435 1:STN:280:DyaL38%2FnsVagsA%3D%3D 10.1002/hep.1840010511 7308988
9. G Mazzella G Saracco D Festi F Rosina S Marchetto F Jaboli R Sostegni A Pezzoli F Azzaroli C Cancellieri M Montagnani E Roda M Rizzetto 1999 Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial Am J Gastroenterol 94 2246 2250 1:CAS:528:DyaK1MXlsFWntLc%3D 10.1111/j.1572-0241.1999.01300.x 10445557
10. J Korenman B Baker J Waggoner JE Everhart AM Di Bisceglie JH Hoofnagle 1991 Long-term remission of chronic hepatitis B after alfa-interferon therapy Ann Intern Med 114 629 634 1:STN:280:DyaK3M7ms1WlsQ%3D%3D 2003708
11. MJ Ter Borg BE Hansen G Bigot BL Haagmans HLA Janssen 2008 ALT and viral load decline during PEG-IFN alfa-2b treatment for HBeAg-positive chronic hepatitis B J Clin Virol 42 160 164 1:CAS:528:DC%2BD1cXms1Wms7k%3D 10.1016/j.jcv.2008.02.007 18359663
12. J Fung CL Lai Y Tanaka M Mizokami J Yuen DK Wong MF Yuen 2009 The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion Am J Gastroenterol 104 1940 1946 1:CAS:528:DC%2BD1MXps1Wqtb8%3D 10.1038/ajg.2009.200 19455108
13. IC Wu ML Shiffman MJ Tong P Marcellin E Mondou D Frederick A Snow-Lampart J Sorbel F Rousseau TT Chang 2008 Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants Clin Infect Dis 47 1305 1311 1:CAS:528:DC%2BD1cXhsVeqs7jK 10.1086/592570 18840078
14. YS Hsu RN Chien CT Yeh IS Sheen HY Chiou CM Chu YF Liaw 2002 Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 1522 1527 10.1053/jhep.2002.33638 12029639
15. JJ Feld EJ Heathcote 2006 Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment Semin Liver Dis 26 116 129 1:CAS:528:DC%2BD28Xltlehu7Y%3D 10.1055/s-2006-939750 16673290
16. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
17. H Zhao F Kurbanov MB Wan YK Yin JQ Niu JL Hou L Wei GQ Wang Y Tanaka M Mizokami CW Si 2007 Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China Clin Infect Dis 44 541 548 1:CAS:528:DC%2BD2sXisVGksrk%3D 10.1086/511042 17243057
18. MF Yuen CK Hui CC Cheng CH Wu YP Lai CL Lai 2001 Long-term follow up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 139 145 1:CAS:528:DC%2BD3MXltlKjsL4%3D 10.1053/jhep.2001.25273 11431745
19. HJ Flink M van Zonneveld BE Hansen RA de Man SW Schalm HL Janssen HBV 99-01 Study Group 2006 Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype Am J Gastroenterol 101 297 303 1:CAS:528:DC%2BD28XitFSgtr4%3D 10.1111/j.1572-0241. 2006.00418.x 16454834
20. EH Buster BE Hansen GK Lau T Piratvisuth S Zeuzem EW Steyerberg HL Janssen 2009 Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 2002 2009 1:CAS:528:DC%2BD1MXhs1SisrzJ 10.1053/j.gastro.2009.08.061 19737568